Date: 2016-05-24
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 24, 2016, Adaptimmune Therapeutics announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee. Barbara Duncan has served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals since May 2009. Ms. Duncan currently serves as a director for public company, Medgenics and for privately held Edgemont Pharmaceuticals. She previously served as Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceuticals, from 2001 to 2009. Before that, she served as Vice President of Corporate Finance - Global Healthcare at Lehman Brothers Inc. and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. Ms. Duncan holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University.
Financial terms:
Latest news:
